Current Policy Priority Successful Effort
FORCE Spearheads Push for High-Risk, Lynch Syndrome Screening Guidelines
USPSTF Agrees to Develop National Recommendations
December 17, 2021 – Today, FORCE was notified that the U.S. Preventive Services Task Force (USPSTF) has agreed to add “Lynch Syndrome-Related Cancers: Risk Assessment, Genetic Counseling, and Genetic Testing” to its list of preventive services under consideration. This is a victory for the hereditary cancer community and individuals at increased risk of colorectal and related cancers because it will raise awareness of Lynch and similar cancer syndromes, identify more people at increased risk of these cancers, and ensure health insurance coverage of genetic testing for these predispositions with no cost-sharing for patients who qualify.
In February 2021, FORCE spearheaded an effort to ask the USPSTF to develop Lynch syndrome screening recommendations to help identify individuals at increased risk of hereditary colorectal (CRC) and related cancers. The USPSTF is a panel of experts in prevention and evidence-based medicine that reviews and develops guidelines on a broad range of preventive services. These recommendations are published to guide primary care providers in determining appropriate screening and preventive care—and to inform insurance coverage of specific preventive services.
Affecting one in 300 Americans, Lynch syndrome is more common than BRCA mutations. The USPSTF developed BRCA mutation screening recommendations in 2013 (updated in 2019) but hasn't provided guidance on screening for other inherited genetic mutations associated with an increased risk of cancer. Colorectal cancer is the third most common cancer and the second leading cause of cancer death in the U.S. Earlier, more intensive screening with colonoscopy may reduce CRC incidence by over 65% among individuals with Lynch syndrome.
USPSTF recommendations will aid in the diagnosis of Lynch syndrome in people without cancer and allow for potentially life-saving cancer screening and prevention options. In addition, a favorable recommendation would facilitate insurance coverage of genetic testing for Lynch syndrome. The Affordable Care Act stipulates that any preventive service receiving a USPSTF rating of "A" or "B" must be covered by most health plans with no patient copay or cost-sharing. Consequently, these guidelines impact access to care for many Americans.
In November 2021, FORCE submitted comments on the USPSTF draft Recommendation Statement for Colorectal Cancer Screening. Previous guidelines recommended that people at average risk of CRC start screening for the disease at age 50. The updated guidelines endorse beginning CRC screening five years earlier—at age 45—for individuals without an increased risk of the disease.
FORCE agrees with the new recommendation for the general population but expressed concern that the Task Force does not provide sufficient guidance on identifying people who may be at increased risk of CRC due to hereditary/genetic factors. The USPSTF mentions that rates of colorectal cancer are higher in certain populations including, “Black adults and persons with a family history of colorectal cancer (even in the absence of any known inherited syndrome such as Lynch syndrome or familial adenomatous polyposis).” However, it does not provide information on how to identify people with Lynch or other CRC syndromes; and, it fails to acknowledge that endometrial, ovarian, pancreatic, urothelial and gastric cancers are associated with hereditary CRC syndromes.
The Task Force did not expand its recommendation by providing information to assist primary care providers in assessing potential hereditary CRC risk in their patients, and referring them for genetic counseling and testing if appropriate. This motivated us to ask the USPSTF to develop guidelines specifically aimed at screening and identifying people who may carry an inherited Lynch syndrome gene mutation. The development of new Task Force recommendations is an intensive process that can take two or more years. We will keep the community updated as the process progresses.
Read our comments on the USPSTF draft Recommendation Statement for Colorectal Cancer Screening and the Lynch Syndrome-Related Cancers: Risk Assessment, Genetic Counseling, and Genetic Testing” nomination.
4/25/2022 - FORCE added its support to an effort spearheaded by SNMMI asking the House Energy and Commerce and Ways and Means Committee Leadership to schedule a hearing on the Facilitating Innovative Nuclear Diagnostics (FIND) Act.
5/2022 - Joined a coalition letter to the HHS Secretary emphasizing that regulatory reform of the framework for clinical laboratory diagnostics is essential to protect patients and ensure access to innovative, high-quality diagnostic tests.
3/29/2022 - Signed on in support of the Right Drug Dose Now (Right) Act, which will advance utilization of evidence-based pharmacogenomic (PGx) information in clinical practice, advance precision medicine, and improve quality of care.